Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
(+)-JQ1
CHF 0.00
In stock
SYN-3004-M0011 mgCHF 177.00
SYN-3004-M0055 mgCHF 298.00
SYN-3004-M01010 mgCHF 518.00
SYN-3004-M05050 mgCHF 1'483.00
SYN-3004-M100100 mgINQ
Product Details | |
---|---|
Product Type | Chemical |
Properties | |
Formula | C23H25ClN4O2S |
MW | 457.0 |
CAS | 1268524-70-4 |
Purity Chemicals | ≥95% |
Appearance | Solid. |
Solubility | Soluble in DMSO or ethanol. |
Declaration | Manufactured by SynKinase. |
Other Product Data | Target: BET bromodomain | Kinase Group: N/A | Substrate: N/A |
InChi Key | DNVXATUJJDPFDM-KRWDZBQOSA-N |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Documents | |
MSDS | Inquire |
Product Specification Sheet | |
Datasheet | Download PDF |
Description
(+)-JQ1 is a potent, high affinity, selective BET bromodomain inhibitor (IC(50) values of 17.7, 32.6, 76.9 and 12942nM respectively for BRD2 (N-terminal (N)), BRD4 (C-terminal (C)), BRD4 (N) and CREBBP, respectively. In binding assays, (+)-JQ1 binds competitive with acetyl lysine to BRD4 bromodomain 1 (Kd=50nM) and and BRD4 bromodomain 2 (Kd=90 nM). May be a useful chemical probe to investigate the role of BET bromodomains in the transcriptional regulation of oncogenesis. (+)-JQ1 exhibited strong dose- and time-dependent inhibition of BRDT, a bromodomain-containing protein highly enriched in testis. BRDT is involved in chromatin remodeling and is essential for healthy sperm development. (+)-JQ1 appears to block that function and causes a decrease in sperm viability, being examined as a potential male contraceptive.
Inhibitor of inflammation and bone destruction.
Product References
- Selective inhibition of BET bromodomains: P. Filippakopoulos, et al.; Nature 468, 1067 (2010)
- BET inhibitor JQ1 blocks inflammation and bone destruction: S. Meng, et al.; J. Dent. Res. 93, 657 (2014)